[go: up one dir, main page]

PE20200295A1 - Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas - Google Patents

Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas

Info

Publication number
PE20200295A1
PE20200295A1 PE2019002554A PE2019002554A PE20200295A1 PE 20200295 A1 PE20200295 A1 PE 20200295A1 PE 2019002554 A PE2019002554 A PE 2019002554A PE 2019002554 A PE2019002554 A PE 2019002554A PE 20200295 A1 PE20200295 A1 PE 20200295A1
Authority
PE
Peru
Prior art keywords
mitoocetoscines
mitochondria
cancer cells
therapeutic agents
agents based
Prior art date
Application number
PE2019002554A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of PE20200295A1 publication Critical patent/PE20200295A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/14—Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computing Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE A COMPUESTOS MITOCETOSCINA DE FORMULA (I) DONDE R ES H, F, CARBOXILO, ENTRE OTROS, DONDE DICHOS COMPUESTOS SE ENLAZAN A POR LO MENOS UNA DE ACAT1 Y OXCT1, INHIBIENDO LA PRODUCCION MITOCONDRIAL DE ATP. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE CANCER, INFECCIONES BACTERIANAS Y LEVADURA PATOGENA
PE2019002554A 2017-06-26 2018-06-25 Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas PE20200295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524829P 2017-06-26 2017-06-26
PCT/US2018/039354 WO2019005698A1 (en) 2017-06-26 2018-06-25 MITOCETOSCINES: MITOCHONDRIAL THERAPEUTIC AGENTS TARGETING THE METABOLISM OF KETONES IN CANCER CELLS

Publications (1)

Publication Number Publication Date
PE20200295A1 true PE20200295A1 (es) 2020-02-05

Family

ID=64742979

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002554A PE20200295A1 (es) 2017-06-26 2018-06-25 Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas
PE2024001838A PE20242070A1 (es) 2017-06-26 2018-06-25 Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2024001838A PE20242070A1 (es) 2017-06-26 2018-06-25 Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas

Country Status (22)

Country Link
US (2) US11667639B2 (es)
EP (1) EP3644988B1 (es)
JP (1) JP7397672B2 (es)
KR (2) KR102854338B1 (es)
CN (1) CN110913854B (es)
AU (2) AU2018292283B2 (es)
BR (1) BR112019026097A2 (es)
CA (1) CA3064452A1 (es)
CL (1) CL2019003708A1 (es)
CO (1) CO2019014259A2 (es)
CR (1) CR20200033A (es)
CU (1) CU20190106A7 (es)
DO (2) DOP2019000312A (es)
EC (1) ECSP20001729A (es)
IL (2) IL292109B2 (es)
MX (1) MX2019014806A (es)
PE (2) PE20200295A1 (es)
PH (1) PH12019502892A1 (es)
RU (1) RU2020102908A (es)
SG (1) SG11201913134UA (es)
WO (1) WO2019005698A1 (es)
ZA (2) ZA201907831B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11667639B2 (en) * 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
WO2019075226A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC
CA3081558A1 (en) * 2017-11-03 2019-05-09 Bioimics Ab Anti-infective heterocyclic compounds and uses thereof
US12188936B2 (en) 2018-06-01 2025-01-07 Lunella Biotech, Inc. Biomarkers and therapeutics for endocrine therapy resistance
AU2019353002B2 (en) 2018-10-02 2024-11-14 Lunella Biotech, Inc. Azithromycin and roxithromycin derivatives as senolytic drugs
US11672810B2 (en) 2019-05-24 2023-06-13 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
EP0758549A4 (en) 1994-04-26 1997-07-02 Nobuhiro Narita MEDICAL COMPOSITION AS A MEDICINE FOR NON-SMALL CELL CANCER
CA2219277A1 (en) 1995-05-03 1996-11-07 Pfizer Limited Novel tetracycline derivatives
WO1999026954A1 (en) 1997-11-25 1999-06-03 University Of Otago Mitochondrially targeted antioxidants
DE69919769T2 (de) 1998-03-03 2005-01-27 Pfizer Products Inc., Groton 3,6-Ketal-Makrolidantibiotika
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
MY140849A (en) 2003-07-07 2010-01-29 Kowa Co 2, 4-bis (trifluoroethoxy) pyridine compound and drug containing the compound
US20070105937A1 (en) * 2003-12-22 2007-05-10 Miguel Pappolla Indole-3-propionamide and derivatives thereof
CA2557216A1 (en) 2004-02-26 2005-09-09 Advanced Ocular Systems Limited Heparin for the treatment of ocular pathologies
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006106440A1 (en) 2005-01-14 2006-10-12 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
KR20130028149A (ko) 2005-07-18 2013-03-18 바이파 사이언스 인코포레이티드 암의 치료
US20080045589A1 (en) 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
WO2007143212A1 (en) 2006-06-02 2007-12-13 Ariad Gene Therapeutics, Inc. Capecitabine combination therapy
US20070292906A1 (en) 2006-06-14 2007-12-20 Bristol-Myers Squibb Company Assay for measuring acyltransferase activity
US20100120679A1 (en) 2006-10-30 2010-05-13 Southern Research Institute Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
WO2009015214A2 (en) 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
AU2008307544A1 (en) 2007-10-02 2009-04-09 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
KR20120008056A (ko) 2009-04-17 2012-01-25 콜비 파마수티컬 컴퍼니 산화 스트레스 조절제(ｏｓｍ)를 포함하는 약제학적 활성 조성물, 신규한 화학 물질, 조성물 및 용도
JP2012527231A (ja) 2009-05-20 2012-11-08 ユニヴァーシテ ド ジュネーヴ 癌開始細胞のミトコンドリア活性阻害剤及びその使用
CN109224064A (zh) 2009-12-04 2019-01-18 昂科免疫有限公司 低氧诱导因子抑制剂的用途
US8673587B2 (en) 2010-05-04 2014-03-18 Trustees Of Dartmouth College Methods for identifying allosteric and other novel acyl-coenzyme A:cholesterol acyltransferase inhibitors
WO2012024612A1 (en) * 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US20130172430A1 (en) 2010-12-10 2013-07-04 Michael P. Lisanti Prognosis and treatment of breast cancer
KR20140057414A (ko) 2011-06-22 2014-05-12 바이옴 바이오사이언스 피브이티. 엘티디. 컨쥬게이트계 항진균 및 항세균 프로드러그
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
US9801922B2 (en) 2011-08-03 2017-10-31 University Of Iowa Research Foundation Compositions and methods of treating cancer
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
KR20140072090A (ko) * 2011-09-09 2014-06-12 뉴욕 유니버시티 ＲＯＲγｔ 조정제로서의 아미도 화합물 및 이의 용도
US9775855B2 (en) 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
US9394233B2 (en) 2012-03-01 2016-07-19 Cincinnati Children's Hospital Medical Center ROS-activated compounds as selective anti-cancer therapeutics
WO2014036037A1 (en) 2012-08-28 2014-03-06 Annam Biosciences, Llc N-boc-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
EP3016715A4 (en) 2013-07-01 2017-02-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
CA2843943A1 (en) 2014-02-20 2014-05-28 Pankaj Modi Oral formulations of chemotherapeutic agents
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
WO2016059247A1 (en) 2014-10-17 2016-04-21 Targeted Therapies Research And Consulting Centre Sprl (Ttrcc) Multi-ingredient pharmaceutical composition for use in cancer therapy
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
KR20180058716A (ko) 2015-10-06 2018-06-01 레드힐 바이오파마 엘티디 암을 치료하기 위한 병용 요법
WO2018027252A1 (en) 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
EP3570856A2 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
US20190365830A1 (en) 2017-01-18 2019-12-05 Evelo Biosciences, Inc. Methods of treating cancer
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
US11667639B2 (en) * 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Also Published As

Publication number Publication date
AU2020257159A1 (en) 2020-11-19
IL270774A (en) 2020-01-30
JP2020525009A (ja) 2020-08-27
KR102854338B1 (ko) 2025-09-03
CA3064452A1 (en) 2019-01-03
KR102646172B1 (ko) 2024-03-13
DOP2019000312A (es) 2020-03-15
KR20200018814A (ko) 2020-02-20
KR20240038805A (ko) 2024-03-25
CN110913854A (zh) 2020-03-24
CO2019014259A2 (es) 2020-04-01
CN110913854B (zh) 2023-04-28
PH12019502892A1 (en) 2020-12-07
JP7397672B2 (ja) 2023-12-13
IL292109B2 (en) 2024-02-01
US20200207775A1 (en) 2020-07-02
RU2020102908A (ru) 2021-07-27
US11667639B2 (en) 2023-06-06
IL292109A (en) 2022-06-01
EP3644988A4 (en) 2021-03-03
AU2018292283A1 (en) 2019-12-12
DOP2022000142A (es) 2022-09-30
SG11201913134UA (en) 2020-01-30
BR112019026097A2 (pt) 2020-07-07
AU2020257159B2 (en) 2022-07-14
RU2020102908A3 (es) 2021-11-15
IL292109B1 (en) 2023-10-01
EP3644988B1 (en) 2023-02-22
ECSP20001729A (es) 2020-02-28
EP3644988A1 (en) 2020-05-06
US11667640B2 (en) 2023-06-06
WO2019005698A1 (en) 2019-01-03
US20200148688A1 (en) 2020-05-14
CU20190106A7 (es) 2020-11-30
CL2019003708A1 (es) 2020-05-15
PE20242070A1 (es) 2024-10-18
MX2019014806A (es) 2020-02-10
ZA201907831B (en) 2022-07-27
ZA202101954B (en) 2022-09-28
CR20200033A (es) 2020-03-05
AU2018292283B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
PE20200295A1 (es) Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
ECSP19082194A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
DOP2022000165A (es) MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
MX383590B (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
MX2017007829A (es) Composicion antimicrobiana.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2019006327A (es) Composicion farmaceutica para prevenir o tratar cancer de higado, que comprende polimorfo cristalino de hexoxido de tetraarsenico.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2020004211A (es) Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial.
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2018002533A (es) Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos